Italian screening protocol and genotypes characterization for HCV elimination (2022-2023) in Ferrara's province: a real-world study.

Hepatitis C virus (HCV) is a worldwide health hazard, and in chronic form (nowadays affecting 50 million people - World Health Organization data) can be lethal. To forestall it, preventive screening is a mandatory approach. Since 2021, Italy conducts a national-wide screening program to eliminate the virus from its population. The team perfected an innovative method throughout the period between 2022 and 2023, to answer that medical necessity and map HCV genotypes. The medical protocol has introduced a dedicated double invitation model for the adherents, with consequential pre-prepared medical consumables allocated. The population was divided in three separate groups: born between 1969 and 1989, addiction services, and prison. Two screening levels were carried out: anti-HCV antibodies (indirect chemiluminescence immunoassay) and quantitative HCV RNA reverse transcription. 51,283 adherents were registered: 447 resulted positive to the first screening round, and 88 to the second (393 and 77 patients respectively from population born between 1969 and 1989). The medical protocol introduced allowed to substantially increase patients and medical staff compliance to HCV screening (adherence: 51.83%, the highest in Italy). HCV genotypes' distribution was mapped by patients' age, biological sex and origin over five groups comprehending subtypes 1a(35.06% of the positive population), 1b(27.27%), 2a/2c(10.39%), 3a(22.08%), 4a/4c/4d(5.19%).